CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 838-847

  Gvozdenovic, Ana ^a   Arlt, Matthias J E ^a   Campanile, Carmen ^a   Brennecke, Patrick ^a   Husmann, Knut ^a   Li, Yufei ^a,b   Born, Walter ^a   Muff, Roman ^a   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

CD44; chemoresistance; hyaluronan; metastasis; osteosarcoma

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; ANIMAL; CELL ADHESION; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SCID MOUSE; SECONDARY; TIBIA; TREATMENT OUTCOME; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD44; CARCINOGENESIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYALURONIC ACID; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICE, SCID; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; TIBIA; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84875301434     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1817     Document Type: Article

References (40)

1. Picci P., Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 2: 6.
2. Ritter J, Bielack SS., Osteosarcoma. Ann Oncol. 2010; 21 (Suppl 7): vii320-5.
3. Ta H, Dass C, Choong P, Dunstan DE., Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009; 28: 247-63.
4. Marina N, Gebhardt M, Teot L, Gorlick R., Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-41.
5. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G., Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32: 423-36.
6. Gorlick R, Khanna C., Osteosarcoma. J Bone Miner Res. 2010; 25: 683-91.
7. Meyers PA, Gorlick R., Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973-89.
8. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y., CD44 in cancer. Crit Rev Clin Lab Sci. 2002; 39: 527-79.
9. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B., CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990; 61: 1303-13.
10. Ponta H, Sherman L, Herrlich PA., CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4: 33-45.
11. Marhaba R, Zoller M., CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35: 211-31.
12. Bacac M, Stamenkovic I., Metastatic cancer cell. Annu Rev Pathol. 2008; 3: 221-47.
13. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S., Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS.J. 2011; 278: 1429-43.
14. Orian-Rousseau V., CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010; 46: 1271-7.
15. Zoller M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer. 2011; 11: 254-67.
16. Xu Y, Stamenkovic I, Yu Q., CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010; 70: 2455-64.
17. Misra S, Ghatak S, Toole BP., Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem. 2005; 280: 20310-5.
18. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH., Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res. 2002; (396): 184-90.
19. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H., Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol. 1999; 125: 646-52.
20. Boldrini E, Peres SV, Morini S, de Camargo B., Immunoexpression of Ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol. 2010; 32: e213-7.
21. Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y, Ishiguro N., Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol. 2007; 171: 274-86.
22. Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K, Kozawa E, Futamura N, Ishiguro N., Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 2011; 105: 1839-49.
23. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R., Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983; 106 Suppl: 21-4.
24. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP., Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844-7.
25. Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W, Fuchs B., Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res. 2011; 27: 58-67.
26. Ruifrok AC, Johnston DA., Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001; 23: 291-9.
27. Arlt MJ, Banke IJ, Walters DK, Puskas GJ, Steinmann P, Muff R, Born W, Fuchs B., LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis. J Orthop Res. 2011; 29: 938-46.
28. Steinmann P, Walters DK, Arlt MJ, Banke IJ, Ziegler U, Langsam B, Arbiser J, Muff R, Born W, Fuchs B., Antimetastatic activity of honokiol in osteosarcoma. Cancer. 2012; 118: 2117-27.
29. Clark JC, Dass CR, Choong PF., A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008; 134: 281-97.
30. Siclari VA, Qin L., Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010; 5: 78.
31. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C., CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121: 1064-74.
32. Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, Feng L, Yang Y., Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med. 2009; 32: E180-8.
33. Rabin K, Man TK, Lau CC., Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62: 173-85; discussion 85-8.
34. Richter U, Wicklein D, Geleff S, Schumacher U., The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012; 137: 687-95.
35. Toole BP, Slomiany MG., Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol. 2008; 18: 244-50.
36. Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, Tominaga S, Nishio K, Tanabe KK, Takahashi K., Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett. 2007; 252: 225-34.
37. Gilg AG, Tye SL, Tolliver LB, Wheeler WG, Visconti RP, Duncan JD, Kostova FV, Bolds LN, Toole BP, Maria BL., Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res. 2008; 14: 1804-13.
38. Bourguignon LY, Peyrollier K, Xia W, Gilad E., Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008; 283: 17635-51.
39. Bates RC, Edwards NS, Burns GF, Fisher DE., A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001; 61: 5275-83.
40. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, Maria BL, Toole BP., Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009; 69: 4992-8.